Ernexa Therapeutics (NASDAQ:ERNA) Issues Quarterly Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) posted its quarterly earnings results on Monday. The company reported ($6.95) earnings per share (EPS) for the quarter, Zacks reports.

Ernexa Therapeutics Trading Up 78.9%

Ernexa Therapeutics stock traded up $5.69 during mid-day trading on Tuesday, hitting $12.90. The stock had a trading volume of 16,644,269 shares, compared to its average volume of 1,080,596. The stock has a 50-day simple moving average of $5.89 and a two-hundred day simple moving average of $20.80. The stock has a market capitalization of $15.09 million, a PE ratio of -0.17 and a beta of 1.88. Ernexa Therapeutics has a 12 month low of $3.18 and a 12 month high of $100.46.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ERNA shares. Wall Street Zen upgraded Ernexa Therapeutics to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. Finally, Brookline Capital Markets started coverage on Ernexa Therapeutics in a report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Ernexa Therapeutics currently has an average rating of “Hold” and a consensus target price of $30.00.

Key Headlines Impacting Ernexa Therapeutics

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, signaling confidence in the company’s longer-term outlook despite recent losses. Brookline Capital Markets earnings estimates for ERNA
• Neutral Sentiment: Ernexa Therapeutics released a virtual investor KOL Connect segment focused on the ovarian cancer landscape and its lead candidate, ERNA-101, which may help keep investor attention on the pipeline. ERNA-101 investor update article
• Negative Sentiment: The company reported a much wider-than-expected quarterly loss of ($6.95) per share, well below the consensus estimate of ($1.95), highlighting ongoing profitability pressure. ERNA earnings miss
• Negative Sentiment: Trading in ERNA was halted multiple times this morning due to LULD pauses, reflecting extreme volatility and rapid price swings that often accompany thinly traded biotech names. ERNA trading halts

Hedge Funds Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new stake in Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.